Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.80 |
| ▸ | BCL2 | P10415 | 9/20 | 0.80 |
| ▸ | MDM4 | O15151 | 1/20 | 0.80 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | BID | P55957 | 1/20 | 0.80 |
| ▸ | BAX | Q07812 | 1/20 | 0.80 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.80 |
| ▸ | ASPH | Q12797 | 1/20 | 0.80 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.80 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.80 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.80 |
| ▸ | BAD | Q92934 | 1/20 | 0.80 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437307 | 0.91 | BCL2L1 (0.80) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL28396797 | 0.91 | BCL2L1 (0.78) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL29355185 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL170470 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL1541072 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL158942 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL2022329 | 0.89 | BCL2L1 (0.90) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL22264451 | 0.89 | BCL2L1 (0.73) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540670 | 0.87 | BCL2L1 (0.93) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1541470 | 0.87 | BCL2L1 (0.84) | BCL2L1BCL2MDM4BCL2L11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | disclosed |
| US-7973161-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2011-06-16 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144112-A9 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | BCL2L1 3/4885BCL2 4/4885MDM4 1653/4885 |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.